FRX News 100.04 06/25/2014 04:55:44 Forest Laboratories (FRX

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Forest Laboratories (FRX) 100.04 $FRX

Affiliated Managers Group Set to Join S&P 500; LaSalle Hotel Properties, Rayonier Advanced Materials, TimkenSteel, Belden to Join the S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire - Tue Jun 24, 5:50PM CDT
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:

Forest Laboratories Reports Positive Data on Viibryd - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 5:20PM CDT
Forest Laboratories, Inc. (FRX) announced positive top-line results from three phase III trials evaluating the efficacy, safety and tolerability of Viibryd in adults suffering from generalized anxiety disorder.

Forest Laboratories (FRX) Breaks Through Resistance at $99.51
Comtex SmarTrend(R) - Tue Jun 24, 10:12AM CDT
Forest Laboratories (NYSE:FRX) has opened bullishly above the pivot of $98.69 today and has reached the first level of resistance at $99.51. Investors may be interested in a cross of the next upside pivot targets of $100.28 and $101.87.

Actavis and Forest Announce Tentative Election Deadline of June 27, 2014
Business Wire - Tue Jun 24, 7:30AM CDT
Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis' planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27, 2014 (the "Election Deadline" . The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1, 2014. Forest stockholders who hold shares through a bank, broker, trust company or other nominee may have an earlier election deadline and should carefully review any instructions received from their bank, broker, trust company or other nominee.

Forest Laboratories, Inc. Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)
Business Wire - Mon Jun 23, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD). In two flexible-dose and one fixed-dose GAD trials, patients who received vilazodone demonstrated statistically significant improvement from baseline in the Hamilton Rating Scale for Anxiety (HAM-A) total score versus placebo at week 8, the primary endpoint.

3 Stocks Driving The Health Care Sector Higher
at The Street - Mon Jun 23, 12:09PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Trade-Ideas: Forest Laboratories (FRX) Is Today's Momo Momentum Stock
at The Street - Mon Jun 23, 9:01AM CDT
Trade-Ideas LLC identified Forest Laboratories (FRX) as a momo momentum candidate

Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
Business Wire - Mon Jun 23, 7:30AM CDT
--- Proven Development Track Record in Key Therapeutic Categories including Women's Health, Psychiatric and Cardiovascular -

Forest Laboratories, Inc. to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress
Business Wire - Fri Jun 20, 3:05PM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that data on the investigational drug cariprazine will be presented at the International College of Neuropsychopharmacology (CINP) 29th World Congress, scheduled June 22-26, 2014 in Vancouver, Canada.

Research and Markets: Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
Business Wire - Fri Jun 20, 10:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vvmps/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023
M2 - Fri Jun 20, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d7b94m/cariprazine) has announced the addition of the "Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering. Cariprazine (RGH-188) is being developed as an adjunctive treatment to antidepressant therapy in patients with MDD who had an inadequate response to antidepressant therapy, and as of April 2014, two Phase III clinical trials were ongoing (Forest Laboratories, NCT01715805; Forest Laboratories, NCT01838876). In addition, cariprazine is being developed for the treatment of schizophrenia and bipolar disorder. Scope - Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Cariprazine including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Cariprazine for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Classification - Symptoms and Subtypes of Major Depressive Disorder - Prognosis - Quality of Life 4 Disease Management - Diagnosis - Treatment Guidelines and Leading Prescribed Drugs - Clinical Practice 5 Competitive Assessment 6 Unmet Needs and Opportunities - More Effective Pharmacotherapies - More Favorable Side Effect Profiles - Rapid Onset of Antidepressant Effects - Personalized Treatment Approach 7 Pipeline Assessment 8 Cariprazine (RGH-188) 9 Appendix For more information visit http://www.researchandmarkets.com/research/d7...ariprazine

Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.

Will Forest Laboratories (FRX) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 7:50AM CDT
Recent estimates have been moving higher for Forest Laboratories.

Forest Laboratories acquires extended US market pediatric exclusivity for NAMENDA and NAMENDA XR by six months
M2 - Thu Jun 19, 4:56AM CDT
Pharmaceutical company Forest Laboratories (NYSE:FRX) said on Wednesday that it has received the US Food and Drug Administration's (FDA) pediatric exclusivity for memantine hydrochloride.

Nasdaq, S&P 500 Rally To New Highs After Fed Meeting
at Investor's Business Daily - Wed Jun 18, 3:20PM CDT
The major averages rallied after the Fed said it would keep interest rates near zero and trimmed monthly bond purchases by $10 billion, to $35 billion. The Fed lowered its 2014 economic growth forecast to between 2.1% and 2.3%, from 2.9%, but said...

Next Resistance Level for Forest Laboratories (FRX) is $99.30
Comtex SmarTrend(R) - Wed Jun 18, 9:02AM CDT
Shares of Forest Laboratories (NYSE:FRX) have bullishly opened above the pivot of $96.19 today and have reached the first resistance level of $97.94. Analysts will be watching for a cross of the next upside pivot targets of $99.30 and $102.41.

Forest Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA(R) and NAMENDA XR(R)
Business Wire - Wed Jun 18, 7:30AM CDT
Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.S Food and Drug Administration (FDA) has granted pediatric exclusivity for memantine hydrochloride. Based on this decision, an additional six months of U.S. market exclusivity will attach to the patents that are listed in FDA's Orange Book for NAMENDA and NAMENDA XR.

Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 73

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
First Horizon Opens Its Charlotte Office in South End

Updated Category News Views 161

A Building Is Not a Balance Sheet Charlotte got a fresh First Horizon sign at 110 East Boulevard on Nov. 19, 2026, and that is a sensible move, not a magic trick. The bank has officially opened a corporate office in the city’s South End neighborhood, positioning the team to develop client relationships across the Charlotte area and broaden its regional footprint. That...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 41

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 21

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 42

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 80

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 45

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 104

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 0

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrate the Festive Spirit with Jekyll Island Clubs' Events

Updated Category News Views 65

Experience the Magic of the Holiday Season at Jekyll Island If you’ve ever kept your Christmas lights up all year round or find yourself shopping for gifts as soon as summer ends, the Jekyll Island Club Resort is the place to be this holiday season. With festivities kicking off earlier each year, both the Jekyll Island Club and the adjoining Ocean Club are gearing up to...

Continue Reading
Uber-Lawyer Deal Balances Rights and Safety in CA

Updated Category News Views 51

California's Uber Compromise: Navigating a Tricky Landscape Holy moly, it looks like we've got ourselves a piece of legislation that tightrope-walks the chaos between Uber, Lyft, and the California ballot. This isn't just another boardroom drama—it's a real, messy tug-of-war that gets to the heart of what it means to keep riders safe without drowning in legal...

Continue Reading
Hurricane Milton's Devastating Potential: Stocks to Monitor

Updated Category News Views 128

Hurricane Milton’s Threat to Industries The looming arrival of Hurricane Milton poses significant risks to multiple sectors, including insurance, utilities, banking, and tourism. As it approaches Florida, analysts are focusing on how this storm could impact stocks and local economies. Hurricane Milton Update The storm has been officially downgraded to a Category 4 as it...

Continue Reading
Why Sports Betting Companies Face Major Challenges Ahead

Updated Category News Views 254

Understanding the Decline of Sports Betting Stocks Recently, the sports betting industry has seen significant stock declines, sparked by a combination of market downturns and regulatory setbacks. Investors have been on edge, especially considering the overall market turbulence characterized by a substantial drop in major indices. Companies like DraftKings and Flutter...

Continue Reading
Veterans Guardian Empowers Veterans with New Clinic Initiative

Updated Category News Views 177

Veterans Guardian Hosts Inaugural VA Disability Claims Assistance Clinic The Veterans Guardian and the Black Veterans Empowerment Council have recently taken a significant step in supporting veterans by organizing their first VA Disability Claims Assistance Clinic. This initiative aims to help veterans navigate the complex VA claims process, ensuring they access the...

Continue Reading